Hot Mandate: China-Based VC Strongly Interested In Growth-Stage Healthcare IT and AI & Big Data Applications in Life Sciences

15 Mar

Founded in 2012 and based in Shenzhen, China, a venture capital backed by 79 local corporations manages 150 million CNY fund (~21 million in USD). The firm typically takes exit in 5 to 7 years after investing. While the allocation size can largely vary, the firm mainly focuses on growth-stage companies that already have clinical data or got FDA/CFDA approved.

The firm has strong interests in novel diagnostics technologies, especially IVD, and they pay close attention to healthcare IT, and AI & big data applications in life science. The third hot spot for the frim is medical devices, especially surgical robots. The novel service platform with the technologies of cell or gene area. The firm has a strong focus on companies that can provide solutions on cardiovascular disease, oncology, orthopedics, central nervous system disorders, and Endocrine system disorders.

The firm invests globally but prefers companies with a Chinese angle and the series entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

<span>%d</span> bloggers like this: